AstraZeneca

Doing business in China had become tougher for five consecutive years and only 41 per cent of its members were expecting to have a better time next year, the survey said

The researchers found that Fasenra can be more effective than the oral corticosteroid prednisolone when injected during an attack, also called an exacerbation, which can involve symptoms such

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients with advanced or recurrent endometrial cancer, said AstraZeneca Pharma

Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday's intraday deals

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second quarter ended on September 30, 2024. The drug firm reported a net profit of Rs 52 crore in the July-September quarter of last fiscal. Revenue from operations stood at Rs 408 crore for the period under review compared with Rs 311 crore in the year-ago period, the firm said in a regulatory filing. Shares of the company ended 3.74 per cent lower at Rs 7,133.10 apiece on the BSE.

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast of a mid-teens percentage at constant currency rates for both revenue

Biz of making films and shows needs more such tie-ups if it is to scale up

The Global Innovation and Technology Centre (GITC) in Chennai will be hiring around 1,300 people in the next 18 months, while another 900 will be hired in Bengaluru

AstraZeneca Pharma India Managing Director and Country President, Sanjeev Panchal, talks to Shine Jacob about the company's future plans in an interview

The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023

An AztraZeneca spokesperson said there are no discussions in the US or India as the company is committed to pursuing the opportunity at Speke and are in constructive talks with the UK government

AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024. The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal. Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing. "We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said. Shares of AstraZeneca Pharma on Thursday ended 6.77 per cent lower at Rs 6,613.40 apiece on the BSE.

Not just AstraZeneca, but Pfizer and Roche have also set up their centres in the state

This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai

Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response

Endometrial cancer ranks as the fourth most prevalent cancer among women in the US. In 2022, it affected more than 66,000 patients